Skip to main content
Clinical Trials/NCT03699098
NCT03699098
Completed
Not Applicable

The Incidence and Risk Factors of Radiotherapy Induced Hypothyroidism in Head and Neck Cancer

Cairo University1 site in 1 country101 target enrollmentAugust 1, 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
Cairo University
Enrollment
101
Locations
1
Primary Endpoint
The the incidence of hypothyroidism
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This is a retrospective study with long term follow up to evaluate the incidence, timing and risk factors of radiotherapy induced hypothyroidism in non-thyroid head and neck cancer patients who were treated with RT alone or in combination with surgery and/or chemotherapy.

Detailed Description

For any patient, fixation was done by a thermoplastic mask. CT scan was done at 3mm thickness for the head and neck region. CT images were transferred to the planning system. Three-dimensional conformal RT, intensity-modulated radiotherapy (IMRT) or Volumetric modulated arc therapy (VMAT) was created. All patients were irradiated with once-daily fractionation at 1.8-2.0 Gy/d with 6-MV photon beams for five days a week. The gross target volume (GTV) was treated with a dose of 70Gy and the lymphatic site (CTV) and areas of high risk microscopic disease (CTV) including lymph nose levels received a radiation dose ranging from 54-66 Gy according to its risk. PTV is a circumferential margin of 5mm around CTV. Thyroid function parameters: The patient's serum T4, T3 and TSH levels, were measured during follow up. Clinical hypothyroidism is defined as the increase in TSH above 5.0mIu/ml with a decrease in free thyroxine levels (free T4) in the serum while elevated TSH with normal free T4 levels was labeled as subclinical hypothyroidism .As per institutional values, the normal values intervals of T4 level (7- 25 PMOL/L), T3( 1.5-7 PMOL/L),TSH (0.2-5 mIu/L). The median time to onset of hypothyroidism was defined as the time interval between completion of radiotherapy and first abnormal recorded T3/T4/TSH value. For all treated patients, thyroid gland was delineated and by reviewing the DVH, the V45, V50, V55, V60, V65 and V70 which means the volume of the thyroid gland receiving 45 Gy, 50 Gy, 55Gy, 60 Gy and 70 Gy respectively.

Registry
clinicaltrials.gov
Start Date
August 1, 2017
End Date
June 5, 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ehab Saad

Principal investigator

Cairo University

Eligibility Criteria

Inclusion Criteria

  • Non-thyroid head and neck cancer patients who were treated with RT alone or in combination with surgery and/or chemotherapy

Exclusion Criteria

  • Patients with thyroid gland disease or abnormal thyroid hormone levels before radiotherapy

Outcomes

Primary Outcomes

The the incidence of hypothyroidism

Time Frame: 8 months

Measuring the thyroid function tests

Secondary Outcomes

  • The risk factors of hypothyroidism(8 months)

Study Sites (1)

Loading locations...

Similar Trials